Brief: Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
03/01/2024 12:34
Jan 3 (Reuters) - Apollomics Inc APLM.O :
* APOLLOMICS COMPLETES ENROLLMENT IN PHASE 3 BRIDGING STUDY
OF
UPROLESELAN IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY ACUTE
MYELOID LEUKEMIA
* APOLLOMICS INC: PRIMARY ENDPOINT FOR PHASE 3 BRIDGING
STUDY IS
OVERALL SURVIVAL
Source text for Eikon: ID:nGNX4j48wd
Further company coverage: APLM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering